A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Relapsed or Refractory Acute Myeloid Leukemia Clinical Trial

Official title:

A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05787496
• Other study ID #: NC525-01
• Status: Recruiting
• Phase: Phase 1
• Start date: February 28, 2023
• Est. completion date: May 2025

Study information

• Verified date: April 2024
• Source: NextCure, Inc.
• Contact: Director Clinical Operations at NextCure, Inc.
• Phone: (240) 763-0535
• Email: NCCLin[@]nextcure.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 63
• Est. completion date: May 2025
• Est. primary completion date: May 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The subject is willing to provide written informed consent for the trial.

2. Be = 18 years of age on the day of signing informed consent.

3. Subject has one of the following Myeloid Neoplasms determined by pathology review at the treating institution:

1. Relapsed or Refractory AML, Note: Active, relapsed, or refractory AML is defined as any one of the following:

• Primary induction failure, or (PIF) after 2 or more cycles of therapy,

• First early relapse after a remission duration of fewer than 6 months,

• Relapse refractory to salvage combination chemotherapy second or subsequent relapse, or

• Relapsed or refractory AML with at least 5% blasts by bone marrow biopsy or aspirate, or at least 1% blasts in peripheral blood.

2. Relapsed or Refractory Myelodysplastic syndrome (MDS) after prior hypomethylating agents.

Note: Subject must have sub-type MDS-EB2 with 10-19% blasts by bone marrow biopsy or aspirate.

3. Relapsed or Refractory Chronic myelomonocytic leukemia (CMML) with progressive disease or lack of response to hypomethylating agents

4. A male subject must agree to use approved contraception (based on institutional guidelines) and refrain from sperm donation or expecting to father a child, from Screening through the treatment period and for at least 90 days after the last dose of study treatment.

5. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

1. Not a woman of childbearing potential (WOCBP);

2. A WOCBP agrees to follow approved contraceptive guidance (based on institutional guidelines) from Screening through the treatment period and for at least 90 days after the last dose of study treatment.

6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

7. Life expectancy greater than or equal to 12 weeks as judged by the Investigator.

8. Have adequate organ function as defined in the protocol.

Exclusion Criteria:

1. Has a diagnosis of acute promyelocytic leukemia (M3, APL), accelerated phase or blast crisis of chronic myeloid leukemia.

2. History or presence of clinically relevant CNS pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.

3. Patients with active Central Nervous System (CNS) involvement (such as leukemic infiltration, blast in the spinal fluid, or subjects with extramedullary disease).

4. A WOCBP who has a positive pregnancy test (within 72 hours) prior to treatment.

5. History or evidence of any other clinically significant disorder, condition or disease (e.g., symptomatic congestive heart failure, unstable angina pectoris, symptomatic myocardial infection, uncontrolled cardiac arrhythmia, pericardial disease or heart failure New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patients' risk for toxicity and in the opinion of the Investigator, would pose a risk to patient safety or interfere with the study evaluation, procedures or completion.

6. Chronic respiratory disease or any other medical condition that requires continuous oxygen that in the opinion of the Investigator, would adversely affect his/her participation in this study.

7. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention.

8. Is currently participating in or has participated in a study of the following prior to the first dose of study treatment:

1. An investigational biologic or an investigational device within 4 weeks or 5 half-lives (whichever is longer);

2. An investigational oral agent within 2 weeks or 5 half-lives (whichever is shorter).

9. Has not recovered to = Grade 1 from toxic effects of prior therapy (including prior chemotherapy, immunotherapy and radiation therapy) and/or complications from interventions before starting therapy.

10. Has previously had an allogeneic solid organ transplant.

11. Autologous HSCT within 6 weeks before the start of study treatment.

12. Allogeneic HSCT within 6 months before the start of study treatment.

13. Any active acute or chronic graft-versus-host disease (GvHD), grade 2-4, or active chronic GvHD requiring systemic treatment.

14. Any systemic therapy (e.g. calcineurin inhibitors (CNI), steroids, etc.) against GvHD within 4 weeks before the start of study treatment.

15. Any Grade = 2 persistent non-hematological toxicity related to allogeneic transplant, such as those requiring systemic immunosuppressive therapy.

16. Previous CAR-T therapy.

17. Known concurrent malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry after treatment with curative intent.

18. Has severe hypersensitivity (= Grade 3), known allergy or reaction to Immunoglobulins or NC525, and/or any of their excipients.

19. Uncontrolled systemic fungal, bacterial, viral, or other infection despite appropriate anti-infection treatment at the time of eligibility confirmation.

20. Has a known history of HIV infection.

21. Has a known active chronic hepatitis B infection or chronic hepatitis C infection with the exception of those with an undetectable viral load within 3 months.

22. Has a history or current evidence of any condition, therapy, or laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the subject's participation for the full duration of the study, such that it is not in the best interest of the subject to participate, in the opinion of the treating investigator.

23. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Myelomonocytic, Chronic
• Leukemia, Myelomonocytic, Juvenile
• Myelodysplastic Syndromes
• Neoplasms
• Relapsed or Refractory Acute Myeloid Leukemia

Intervention

Drug:
• NC525
Monoclonal antibody specific for LAIR-1

Locations

Country	Name	City	State
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Massachusetts General Hospital	Boston	Massachusetts
United States	Roswell Park Cancer Institute	Buffalo	New York
United States	Cleveland Clinic	Cleveland	Ohio
United States	University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	City of Hope	Duarte	California
United States	MD Anderson Cancer Center	Houston	Texas
United States	University of Miami	Miami	Florida
United States	Weill Cornell Medicine	New York	New York
United States	Oregon Health & Science University	Portland	Oregon
United States	Washington University School of Medicine in St. Louis	Saint Louis	Missouri

Sponsors (1)

Lead Sponsor	Collaborator
NextCure, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the frequency, duration, and severity of treatment-emergent adverse events [Safety and Tolerability].	Toxicity grading per NCI CTCAE v5.0.	Up to 24 months
Primary	To evaluate dose-limiting toxicities (DLTs) of NC525.	Toxicity grading per NCI CTCAE v5.0.	Up to 56 days
Primary	Define a recommended Phase 2 dose (RP2D) of NC525	A Bayesian Optimal Interval (BOIN) design will be utilized to determine a recommended Phase 2 dose (RP2D) for NC525.	Up to 24 months
Primary	Define a minimally active dose (MAD) of NC525	A BOIN design will be utilized to determine a MAD	Up to 24 months
Primary	Define a pharmacologically active dose (PAD) of NC525	A BOIN design will be utilized to determine a PAD	Up to 24 months
Primary	Define a maximum tolerated dose (MTD) of NC525	A BOIN design will be utilized to determine a MTD	Up to 24 months
Secondary	To evaluate the clinical benefit of NC525 by assessing Objective Response (OR).	Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.	Until disease progression, up to 24 months
Secondary	To evaluate the clinical benefit of NC525 by assessing Event-free survival (EFS).	Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.	Until disease progression, up to 24 months
Secondary	To evaluate the clinical benefit of NC525 by assessing Overall survival (OS).	Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.	Until disease progression, up to 24 months
Secondary	Assessment of time to achieve response, defined as CR, CRi, or CRh	Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures.	Cycle 1 Day 1 to day remission is achieved, up to 24 months (each cycle is 28 days)
Secondary	Maximum Observed Serum Concentration (Cmax) of NC525		During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days)
Secondary	Terminal Half-life (t1/2) of NC525		During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days)
Secondary	Area under the serum concentration versus time curve (AUC) of NC525		During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days)